8:33 am Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment; Dichotomization of improvement in exercise performance from baseline at the 25% and 50% levels were analyzed on the Intent-to-Treat Population – HedgeChatter

8:33 am Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment; Dichotomization of improvement in exercise performance from baseline at the 25% and 50% levels were analyzed on the Intent-to-Treat Population

25 Mar

8:33 am Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment; Dichotomization of improvement in exercise performance from baseline at the 25% and 50% levels were analyzed on the Intent-to-Treat Population

Bystocknews HEB, stock Comments Off

View todays social media effects on HEB

View the latest stocks trending across Twitter. Click to view dashboard

See who Hemispherx is hiring next, click here to view

Author